Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.52 |
| ▸ | CES1 | P23141 | 4/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265533 | 1.00 | CES2 (0.52) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL31035929 | 1.00 | CES2 (0.52) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL15854160 | 1.00 | CES2 (0.52) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL29453648 | 0.82 | CES2 (0.52) | CES2CES1CA3CA6CA5A | |
| SCHEMBL17947416 | 0.82 | CES2 (0.52) | CES2CES1CA3CA6CA5A | |
| SCHEMBL15853708 | 0.82 | CES2 (0.52) | CES2CES1CA3CA6CA5A | |
| SCHEMBL1998132 | 0.82 | CES2 (0.52) | CES2CES1CA3CA6CA5A | |
| SCHEMBL423296 | 0.81 | PSEN1 (0.49) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL16105638 | 0.81 | PSEN1 (0.49) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL24869041 | 0.80 | MEN1 (0.41) | CES2CES1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-05-10 | — | — | US | disclosed |
| CN-106986875-A | The conditioning agent and its application method of 5 HT acceptors | ABBVIE 公司 | 2017-07-28 | — | — | CN | disclosed |
| CN-102482292-B | Modulators of 5-HT receptors and methods of use thereof | ABBVIE 公司 | 2017-07-18 | — | — | CN | disclosed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2421870-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-03-09 | — | — | EP | disclosed |
| CN-105367578-A | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC | 2016-03-02 | — | — | CN | disclosed |
| EP-2522671-B1 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-102958932-B | 5-HT receptor modulators and methods of use thereof | ABBVIE (US) | 2015-11-25 | — | — | CN | disclosed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2013-11-21 | — | — | US | disclosed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8518933-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2566858-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | Pfizer Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| CN-102958932-A | 5-HT receptor modulators and methods of use thereof | ABBVI INC | 2013-03-06 | — | — | CN | disclosed |
| EP-2522671-A2 | Modulators of 5-HT receptors and methods of use thereof | Abbott Laboratories (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CES2 1759/4885CES1 1510/4885PSEN1 734/4885 |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CES2 1759/4885CES1 1510/4885PSEN1 734/4885 |
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CES2 1759/4885CES1 1510/4885PSEN1 734/4885 |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CES2 1759/4885CES1 1510/4885PSEN1 734/4885 |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | CES2 2687/4885CES1 1172/4885PSEN1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.